Market Place
Sourcing Support
IN8bio Shows Positive Phase 1 Data of INB-200 in Newly Diagnosed
02 Jun 2025 //
GLOBENEWSWIRE
IN8bio at 11th Annual Immuno-Oncology 360° Conference 2025
18 Mar 2025 //
GLOBENEWSWIRE
IN8bio Reports Durable in INB-200 Ph 1 Trial at SNO Annual Meeting
25 Nov 2024 //
GLOBENEWSWIRE
IN8bio Reports Q3 2024 Financial Results & Corporate Highlights
12 Nov 2024 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
29 Aug 2024 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright Immune Cell Engager Virtual Conference
24 Jun 2024 //
GLOBENEWSWIRE
IN8bio Announces Upcoming Presentation At EHA 2024 Congress
14 May 2024 //
GLOBENEWSWIRE
IN8bio Q1 2024 Financials And Corporate Highlights
09 May 2024 //
GLOBENEWSWIRE
IN8bio Presents at ASGCT 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
IN8bio to Present at Noble Capital Virtual Healthcare Conference
16 Apr 2024 //
GLOBENEWSWIRE
IN8bio Unveils Gamma-Delta nsCAR-T Data at AACR 2024
09 Apr 2024 //
GLOBENEWSWIRE
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
IN8bio to Present Preclinical Data on Novel Gamma-Delta CAR Platform Candidate
05 Mar 2024 //
GLOBENEWSWIRE
IN8bio to Present at Upcoming Investor Conferences
26 Feb 2024 //
BUSINESSWIRE
IN8bio Highlights Company Accomplishments and Outlines 2024 Pipeline Goals
04 Jan 2024 //
GLOBENEWSWIRE
IN8bio Announces Pricing of Financing Totaling up to $46.9M in Private Placement
11 Dec 2023 //
GLOBENEWSWIRE
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
07 Dec 2023 //
GLOBENEWSWIRE
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12
05 Dec 2023 //
GLOBENEWSWIRE
IN8bio Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Revive Therapeutics Enters into Agreement with Lawson Health Research Institute
06 Nov 2023 //
GLOBENEWSWIRE
IN8bio Presents Positive Data from Induced Pluripotent Stem Cell (iPSC) Platform
03 Nov 2023 //
GLOBENEWSWIRE
IN8bio Strengthens Intellectual Property Portfolio with Granted Global Patents
19 Sep 2023 //
GLOBENEWSWIRE
IN8bio Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
IN8bio Reports First Quarter 2023 Financial Results & Provides Corporate Update
12 May 2023 //
GLOBENEWSWIRE
IN8bio Announces New Preclinical Data in Ovarian Cancer at ASGCT
02 May 2023 //
GLOBENEWSWIRE
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
01 May 2023 //
GLOBENEWSWIRE
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform
17 Apr 2023 //
GLOBENEWSWIRE
IN8bio Reports Fourth Quarter and Reports Full 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform
16 Mar 2023 //
GLOBENEWSWIRE
IN8bio to Present at the Cowen 43rd Annual Healthcare Conference
01 Mar 2023 //
GLOBENEWSWIRE
IN8bio Presents Data Showing Non-Signaling CAR Platform Targets Cancer Cell
23 Feb 2023 //
GLOBENEWSWIRE
IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
21 Feb 2023 //
GLOBENEWSWIRE
IN8bio to Present at the B. Riley Securities Annual Virtual Oncology Conference
17 Jan 2023 //
GLOBENEWSWIRE
IN8bio Announces New Data at ASH Showing 100 Percent of Ph1 Trial of INB-100
12 Dec 2022 //
GLOBENEWSWIRE
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400
08 Dec 2022 //
GLOBENEWSWIRE
IN8bio to Present at November Investor Conferences
01 Nov 2022 //
GLOBENEWSWIRE
IN8bio to Present at Cantor Oncology & HemOnc Conference
27 Sep 2022 //
GLOBENEWSWIRE
IN8bio Partners with the Dunbar CAR T-Cell Program at the University Louisville
15 Sep 2022 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
13 Sep 2022 //
GLOBENEWSWIRE
IN8bio to Present at September Investor and Scientific Conferences
30 Aug 2022 //
GLOBENEWSWIRE
IN8bio Announces to Purchase Additional Shares in Public Offering
19 Aug 2022 //
GLOBENEWSWIRE
IN8bio Announces Closing of $10.25 Mil Public Offering of Common Stock
16 Aug 2022 //
GLOBENEWSWIRE
IN8bio Reports Second Quarter 2022 Financial Results & Provides Corporate Update
12 Aug 2022 //
GLOBENEWSWIRE
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering
11 Aug 2022 //
GLOBENEWSWIRE
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy
21 Jul 2022 //
GLOBENEWSWIRE
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
12 Jul 2022 //
GLOBENEWSWIRE
IN8bio to Present at July Investor and Scientific Conferences
30 Jun 2022 //
GLOBENEWSWIRE
IN8bio Announces Presentation at Jefferies Healthcare Conference and others
08 Jun 2022 //
GLOBENEWSWIRE
IN8bio Announces Positive GBM Clinical Updates from INB-200 PI Trial
06 Jun 2022 //
GLOBENEWSWIRE
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell
17 May 2022 //
GLOBENEWSWIRE
IN8bio Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT
05 May 2022 //
GLOBENEWSWIRE
IN8bio to Present at May Investor and Scientific Conferences
04 May 2022 //
GLOBENEWSWIRE
IN8bio Continues to Build on Clinical, Regulatory Team with Two Key Appointments
13 Apr 2022 //
GLOBENEWSWIRE
IN8bio to Present at April Investor and Scientific Conferences
05 Apr 2022 //
GLOBENEWSWIRE
IN8bio Presents Clinical Update from Ongoing Phase 1 Trial of INB-100
28 Mar 2022 //
GLOBENEWSWIRE
IN8bio Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
IN8bio to present at Bio CEO & Investor Conference and Next Gen CAR-TCR Summit
10 Feb 2022 //
GLOBENEWSWIRE
IN8bio: Clinical Updates from Phase 1 Trial of INB-200
06 Jan 2022 //
GLOBENEWSWIRE
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic
16 Dec 2021 //
YAHOO
